|
시장보고서
상품코드
1463113
길랭 바레 증후군 시장 : 점유율, 규모, 동향, 산업 분석 보고서 : 치료제별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
폴라리스 마켓 리서치의 최근 조사에 따르면 세계의 길랭 바레 증후군 시장 규모는 2032년까지 9억 6,058만 달러에 이를 것으로 예상됩니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
미국 식품의약국(USFDA)에 의한 의약품 승인 촉진 이니셔티브는 제약 업계에서 신제품 승인의 상당한 증가를 촉진하는데 있어 매우 중요한 역할을 하고 있습니다. 이 이니셔티브는 혁신적인 의약품, 특히 언메트 메디컬 니즈에 대응하는 의약품의 개발과 이용을 촉진하는 것을 목적으로 하고 있습니다. USFDA는 규제 과정을 간소화함으로써 제약 회사가 새로운 치료법을 시장에 투입할 수 있는 보다 효율적인 경로를 만들어내고, 궁극적으로 다양한 병리학 환자에게 이익을 가져오고 있습니다.
신제품 승인이 급증하는 주목할 만한 분야 중 하나는 길랭 바레 증후군(GBS) 시장입니다. GBS는 면역계가 말초 신경을 공격하고 근력 저하와 심각한 합병증을 일으킬 수 있음을 특징으로 하는 드문 신경 질환입니다. 의약품의 승인 취득을 가속시키는 것이 중요시되고, GBS 영역에서의 연구개발에 박차가 가해지며 그 결과, 이 질환 특유의 과제에 대처하기 위한 혁신적인 치료법의 도입이 만들어지고 있습니다.
제약회사는 GBS 연구에 대한 투자를 늘리고 있으며, 규제 당국의 합리화된 프로세스를 활용하여 임상시험을 가속화하고 잠재적인 치료법을 보다 빠르게 시장에 투입하고 있습니다. 이것은 GBS 환자에 대한 치료법의 전망을 넓힐 뿐만 아니라, 보다 경쟁적인 시장 환경을 창출하고, 치료법의 추가 혁신과 진보를 촉진하고 있습니다.
의약품 승인 신속화 이니셔티브의 긍정적인 영향은 FDA가 승인한 GBS 치료제의 수가 증가하고 있기 때문인 것이 분명하며 헬스케어 전문가에게 이 과제가 많은 질환을 관리 및 치료하기 위한 새로운 수단을 제공합니다. 제약 업계가 이러한 신속 승인 제도를 계속 채택함으로써, 희귀질환 치료의 정세가 일변할 가능성이 있으며, 길랭 바레 증후군과 같은 질환의 환자에게 희망과 결과의 개선을 가져옵니다.
길랭 바레 증후군 시장 보고서 하이라이트
면역글로불린 점적 제제는 적용이 용이하기 때문에 향후 수년간 가장 높은 성장이 예상되고 있습니다.
면역글로불린 정주 요법의 효능으로 인해 모 약물 시장이 가장 큰 시장 점유율을 차지합니다.
병원 약국 부문은 자가면역 증례 증가로 인해 더 큰 수익 점유율을 차지할 것으로 예측됩니다.
아시아태평양은 노년 인구의 존재와 이 분야의 기술 혁신으로 급성장하고 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 길랭 바레 증후군 시장 인사이트
- 길랭 바레 증후군 시장-유통 채널 스냅샷
- 길랭 바레 증후군 시장 역학
- 성장 촉진요인 및 기회
- 길랭 바레 증후군의 이환율 상승
- 길랭 바레 증후군의 위험 증가
- 억제요인 및 과제
- 치료에 관한 인지도의 낮음이 시장의 성장을 저해할 가능성이 있다
- 성장 촉진요인 및 기회
- PESTEL 분석
- 길랭 바레 증후군 시장의 유통 채널의 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 길랭 바레 증후군 시장 : 치료 분야별
- 주요 조사 결과
- 서문
- 정맥내 면역글로불린
- 혈장 교환
- 기타
제6장 세계의 길랭 바레 증후군 시장 : 투여 경로별
- 주요 조사 결과
- 서문
- 경구
- 부모 대여
제7장 세계의 길랭 바레 증후군 시장 : 유통 채널별
- 주요 조사 결과
- 서문
- 병원 약국
- 소매 약국
- 기타
제8장 세계의 길랭 바레 증후군 시장 : 지역별
- 주요 조사 결과
- 서문
- 길랭 바레 증후군 시장 평가 : 지역별(2019-2032년)
- 길랭 바레 증후군 시장-북미
- 북미 : 길랭 바레 증후군 시장 : 치료 분야별(2019-2032년)
- 북미 : 길랭 바레 증후군 시장 : 유통 채널별(2019-2032년)
- 북미 : 길랭 바레 증후군 시장 : 투여 경로별(2019-2032년)
- 길랭 바레 증후군 시장-미국
- 길랭 바레 증후군 시장-캐나다
- 길랭 바레 증후군 시장-유럽
- 유럽 : 길랭 바레 증후군 시장 : 치료 분야별(2019-2032년)
- 유럽 : 길랭 바레 증후군 시장 : 유통 채널별(2019-2032년)
- 유럽 : 길랭 바레 증후군 시장 : 투여 경로별(2019-2032년)
- 길랭 바레 증후군 시장-영국
- 길랭 바레 증후군 시장-프랑스
- 길랭 바레 증후군 시장-독일
- 길랭 바레 증후군 시장-이탈리아
- 길랭 바레 증후군 시장-스페인
- 길랭 바레 증후군 시장-네덜란드
- 길랭 바레 증후군 시장-러시아
- 길랭 바레 증후군 시장-아시아태평양
- 아시아태평양 : 길랭 바레 증후군 시장 : 치료 분야별(2019-2032년)
- 아시아태평양 : 길랭 바레 증후군 시장 : 유통 채널별(2019-2032년)
- 아시아태평양 : 길랭 바레 증후군 시장 : 투여 경로별(2019-2032년)
- 길랭 바레 증후군 시장-중국
- 길랭 바레 증후군 시장-인도
- 길랭 바레 증후군 시장-말레이시아
- 길랭 바레 증후군 시장-일본
- 길랭 바레 증후군 시장-인도네시아
- 길랭 바레 증후군 시장-한국
- 길랭 바레 증후군 시장-중동 및 아프리카
- 중동 및 아프리카 : 길랭 바레 증후군 시장 : 치료 분야별(2019-2032년)
- 중동 및 아프리카 : 길랭 바레 증후군 시장 : 유통 채널별(2019-2032년)
- 중동 및 아프리카 : 길랭 바레 증후군 시장 : 투여 경로별(2019-2032년)
- 길랭 바레 증후군 시장-사우디아라비아
- 길랭 바레 증후군 시장-UAE
- 길랭 바레 증후군 시장-이스라엘
- 길랭 바레 증후군 시장-남아프리카
- 길랭 바레 증후군 시장-라틴아메리카
- 라틴아메리카 : 길랭 바레 증후군 시장 : 치료 분야별(2019-2032년)
- 라틴아메리카 : 길랭 바레 증후군 시장 : 유통 채널별(2019-2032년)
- 라틴아메리카 : 길랭 바레 증후군 시장 : 투여 경로별(2019-2032년)
- 길랭 바레 증후군 시장-멕시코
- 길랭 바레 증후군 시장-브라질
- 길랭 바레 증후군 시장-아르헨티나
제9장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 파트너십, 협업, 계약 및 전시회
제10장 기업 프로파일
- Annexon Inc.
- Bayer AG
- Biotest AG
- Cellenkos Inc
- China Biologic Products Holdings Inc
- CSL Limited
- Grifols SA
- Kedrion Biopharma Inc
- Octapharma AG
- Takeda Pharmaceutical Company Limited
The global guillain-barre syndrome market size is expected to reach USD 960.58 million by 2032, according to a new study by Polaris Market Research. The report "Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The accelerated drug approval initiative by the United States Food and Drug Administration (USFDA) has played a pivotal role in fostering a significant rise in new product approvals within the pharmaceutical industry. This initiative aims to expedite the development and availability of innovative drugs, particularly those addressing unmet medical needs. By streamlining regulatory processes, the USFDA has created a more efficient pathway for pharmaceutical companies to bring novel treatments to market, ultimately benefiting patients with various medical conditions.
One notable area experiencing a surge in new product approvals is the market for Guillain-Barre Syndrome (GBS). GBS is a rare neurological disorder characterized by the immune system attacking the peripheral nerves, leading to muscle weakness and potentially severe complications. The heightened focus on accelerating drug approvals has spurred research and development efforts in the GBS space, resulting in the introduction of innovative therapies designed to address the unique challenges posed by this disorder.
Pharmaceutical companies are increasingly investing in GBS research, leveraging the streamlined regulatory processes to expedite clinical trials and bring potential treatments to market faster. This has not only broadened the therapeutic landscape for GBS patients but has also created a more competitive market environment, encouraging further innovation and advancements in treatment options.
The positive impact of the accelerated drug approval initiative is evident in the growing number of FDA-approved drugs for GBS, providing healthcare professionals with additional tools to manage and treat this challenging condition. As the pharmaceutical industry continues to embrace these expedited pathways, it holds the potential to transform the landscape of rare disease treatment, offering hope and improved outcomes for patients with conditions like Guillain-Barre Syndrome.
Guillain-Barre Syndrome Market Report Highlights
Intravenous immunoglobulin segment is anticipated to witness the highest growth in the coming years due to its ease of application.
Parental segment accounted for the largest market share owing to its effectiveness in intravenous immunoglobulin therapy.
Hospital Pharmacies segment is projected to experience a larger revenue share due to the growing number of auto-immune cases.
Asia Pacific will grow rapidly, attributable to the presence of a geriatric population, and innovations in the sector
The global players include Annexon, Bayer, Biotest, Cellenkos, China Biologic Products Holdings, CSL Limited, & Grifols.
Polaris Market Research has segmented the Guillain-Barre syndrome market report based on therapeutics, route of administration, distribution channel and region:
Guillain-Barre Syndrome, Therapeutics Outlook (Revenue - USD Million, 2019 - 2032)
- Intravenous Immunoglobulin
- Plasma Exchange
- Others
Guillain-Barre Syndrome, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)
- Oral
- Parental
Guillain-Barre Syndrome, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Guillain-Barre Syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of APAC
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of MEA
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Guillain-Barre Syndrome Market Insights
- 4.1. Guillain-Barre Syndrome Market - Distribution Channel Snapshot
- 4.2. Guillain-Barre Syndrome Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising prevalence of Guillain-Barre syndrome cases
- 4.2.1.2. Increase in the risk of having Guillain-Barre syndrome
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lower awareness about the treatment is likely to impede market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Guillain-Barre Syndrome Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Guillain-Barre Syndrome Market, by Therapeutic Area
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 5.3. Intravenous Immunoglobulin
- 5.3.1. Global Guillain-Barre Syndrome Market, by Intravenous Immunoglobulin, by Region, 2019-2032 (USD Million)
- 5.4. Plasma Exchange
- 5.4.1. Global Guillain-Barre Syndrome Market, by Plasma Exchange, by Region, 2019-2032 (USD Million)
- 5.5. Others
- 5.5.1. Global Guillain-Barre Syndrome Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Guillain-Barre Syndrome Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 6.3. Oral
- 6.3.1. Global Guillain-Barre Syndrome Market, by Oral, by Region, 2019-2032 (USD Million)
- 6.4. Parental
- 6.4.1. Global Guillain-Barre Syndrome Market, by Parental, by Region, 2019-2032 (USD Million)
7. Global Guillain-Barre Syndrome Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Guillain-Barre Syndrome Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Guillain-Barre Syndrome Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Guillain-Barre Syndrome Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Guillain-Barre Syndrome Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Guillain-Barre Syndrome Market - North America
- 8.3.1. North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.2. North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.3. North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.3.4. Guillain-Barre Syndrome Market - U.S.
- 8.3.4.1. U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.3.5. Guillain-Barre Syndrome Market - Canada
- 8.3.5.1. Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4. Guillain-Barre Syndrome Market - Europe
- 8.4.1. Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.2. Europe.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.3. Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.4. Guillain-Barre Syndrome Market - UK
- 8.4.4.1. UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.4.3. UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.5. Guillain-Barre Syndrome Market - France
- 8.4.5.1. France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.5.2. France.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.5.3. France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.6. Guillain-Barre Syndrome Market - Germany
- 8.4.6.1. Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.7. Guillain-Barre Syndrome Market - Italy
- 8.4.7.1. Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.8. Guillain-Barre Syndrome Market - Spain
- 8.4.8.1. Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.9. Guillain-Barre Syndrome Market - Netherlands
- 8.4.9.1. Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.10. Guillain-Barre Syndrome Market - Russia
- 8.4.10.1. Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5. Guillain-Barre Syndrome Market - Asia Pacific
- 8.5.1. Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.4. Guillain-Barre Syndrome Market - China
- 8.5.4.1. China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.4.2. China.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.4.3. China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.5. Guillain-Barre Syndrome Market - India
- 8.5.5.1. India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.5.2. India.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.5.3. India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.6. Guillain-Barre Syndrome Market - Malaysia
- 8.5.6.1. Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.7. Guillain-Barre Syndrome Market - Japan
- 8.5.7.1. Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.8. Guillain-Barre Syndrome Market - Indonesia
- 8.5.8.1. Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.9. Guillain-Barre Syndrome Market - South Korea
- 8.5.9.1. South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6. Guillain-Barre Syndrome Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.4. Guillain-Barre Syndrome Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.5. Guillain-Barre Syndrome Market - UAE
- 8.6.5.1. UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.6. Guillain-Barre Syndrome Market - Israel
- 8.6.6.1. Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.7. Guillain-Barre Syndrome Market - South Africa
- 8.6.7.1. South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7. Guillain-Barre Syndrome Market - Latin America
- 8.7.1. Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.3. Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.4. Guillain-Barre Syndrome Market - Mexico
- 8.7.4.1. Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.5. Guillain-Barre Syndrome Market - Brazil
- 8.7.5.1. Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.6. Guillain-Barre Syndrome Market - Argentina
- 8.7.6.1. Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Annexon Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bayer AG
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Biotest AG
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Cellenkos Inc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. China Biologic Products Holdings Inc
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. CSL Limited
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Grifols S A
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Kedrion Biopharma Inc
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Octapharma AG
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
